Propanc Biopharma Inc (PPCB)

[the gipper]

PROPANC I believe is actively seeking to increase the efficacy of PRP, and that is what this study is about. In one of the recent updates, PPCH stated, "Numerous Preclinical Activities Underway for The Company's Lead Product, PRP:

Animal efficacy studies in several tumor cell lines are underway for PRP with the Company's research partner, vivoPharm, in Hershey, PA. The studies are investigating the optimization of the PRP treatment, which are expected to even further improve PRP's anti-tumor effects compared to the previous pilot studies. The human xenograft orthotopic models (human derived tumors transplanted into immunocompromised mice) will be used to support upcoming regulatory agency meetings and licensing discussions"

The key here is that they are seeking to "further improve PRP's anti-tumor effects compared to previous pilot studies. antithrombin III levels vs maximum seriousness grade of acute is in focus, likely in conjunction with studying the effects of antithrombin levels in patients with compromised Pancreas, either pre-cancerous or already having cancer.
Research has already show PRP to be effective, they are apparently seeking to tweek efficacy by studying various stages of pancreatic disease, and the effects on possible treatment. we should get some clarification from Propanc on this near term Sure looks interesting!